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It has previously been reported that the slow-releasing hydrogen sulfide (H2S) 
donor, GYY4137, exerts anti-cancer activity both in vivo and in vitro. In this 
study, we identified an additional, slow-releasing H2S donor termed FW1010 
(GYY4137 analogue).  In biochemical studies, FW1010 released more H2S over a 
period of 6 days than did GYY4137. FW1010 also caused greater concentration-
dependent killing of several human cancer cell lines than did GYY4137. This was 
brought about by apoptosis. Both GYY4137 and FW1010 significantly and 
concentration dependently increased glucose consumption and lactate production 
in cancer cells. FW1010 was more potent than GYY4137 in this regard. FW1010 
and GYY4137 also concentration-dependently reduced intracellular pH (pHi) in 
cancer cells. Again FW1010 was more potent than GYY4137.  Intriguingly, 
neither GYY4137 nor FW1010 affected cell death, glucose consumption, lactate 
production or pHi in a normal (i.e. non-cancer) cell line.  These experiments 
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Symbols                    Full name 
3MST                        3-mercaptopyruvate sulfurtransferase 
ADT                          Anethole dithiolethione 
ADT-OH                   5-(4-hydroxyphenyl)-3H-1, 2-dithiole-3-thione 
AEs                            Anion exchangers 
AGT II                       Alkyltransferase II 
ATCC                        American Type Culture Collection 
Bcl2                           B-cell lymphoma 2 
BECEF                      2′, 7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein– 
                                  Acetoxymethyl 
CaCl2                         Calcium Chloride 
cAMP                        Cyclic adenosine monophosphate 
CAs                           Carbonic anhydrases 
CaS                           Calcium sulfide 
CAT                          Cysteine aminotransferase 
CBS                           Cysthathionine-β-synthase  
CL                             Cysteine lyase 
CO                             Carbon monoxide 
CO2                           Carbon dioxide  
CSE                           Cystathionine-γ-lyase 
DADS                        Diallyl disulfide 
DATS                        Diallyl trisulfide 
DMEM                      Dulbecco’s modified Eagle’s medium 
FBS                            Fetal calf serum 
EDTA                        Ethylenediaminetetraacetic acid 





FeCl3                         Ferric chloride solution  
GLUT                       Glucose transporter 
GSH                          Glutathione 
GYY4137                 Morpholin-4-ium 4 methoxyphenyl (morpholino)  
                                  Phosphinodithioate 
HKs                           Hexokinases 
H2S                            Hydrogen sulfide 
HS-                                           Hydrosulfide anion 
IC50                                         Half maximal inhibitory concentration 
IL-6                           Interleukin 6 
iNOS                         Inducible nitric oxide synthase 
i.p.                             Intraperitoneal injection 
KCl                            Potassium chloride 
KH2PO4                               Potassium dihydrogen phosphate 
LDH -A                     Lactate dehydrogenase A 
L-NAME                   L-NG-Nitroarginine Methyl Ester  
LPS                            Lipopolysaccharide 
MCTs                        Mononcarboxylate transporters 
MgCl2                        Magnesium Chloride 
MI                              Myocardial infarction 
MPO                          Myeloperoxidase 
MST                          Mercaptopyruvate sulfurtransferase 
Na2S2O4                     Sodium dithionite 
Na2HPO4                   Disodium hydrogen phosphate 
Na2S                          Sodium sulfide 
NAC                          N-acetyl cysteine  





Na3VO4                                Sodium orthovanadate 
NAD+                        Aldehyde dehydrogenase 
NaHCO3                               Sodium bicarbonate 
NaHS                         Sodium hydrosulfide 
NaOH                        Sodium hydroxide 
NF-κB                        Nuclear factor kappa-B 
NH4Cl                        Ammonium chloride 
NHEs                         Sodium/proton exchangers 
NMDA                      N-methyl-B-aspartat 
NNDPD                     N,N-dimethyl-p-phenylenediamine dihydrochloride 
NO                             Nitric oxide 
NOSH-aspirin            Nitric oxide and H2S-releasing derivative of aspirin 
NOSH-1                    (4-(3-thioxo-3H-1,2-dithiol-5-yl) phenyl 2-((4-(nitrooxy)- 
                                   butanoyl)oxy) benzoate) 
NOSH-2                    (4-(nitrooxy) butyl (2-((4-(3-thioxo-3H-1,2-dithiol-5- 
                                   yl)phenoxy)carbonyl)phenyl)) 
NOSH-3                    (4-carbamothioylphenyl 2-((4-(nitrooxy)butanoyl)- 
                                   oxy)benzoate) 
NOSH-4                    (4-(nitrooxy) butyl 2-(5-((R)-1,2-dithiolan-3- 
                                   yl)pentanoyloxy)-benzoate) 
NP-40                        Tergitol-type NP-40 
NSAID                      Non-steroidal anti-inflammatory drug  
NT                             Non-treatment 
PARP                        Poly (ADP-ribose) polymerase 
PBS                           Phosphate-buffered saline 
PHi                            Intracellular pH 





PKM2                       Pyruvate kinase M2 isoform 
PVDF                        Polyvinylidene difluoride 
RIPA                         Radio-Immunoprecipitation Assay 
S-N                            Nitrosothiol 
SAC                          S-allyl cysteine 
SDS-PAGE              Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SO2                                         Sulfur dioxide 
SPC                           S-propyl cysteine 
SPRC                        S-propargyl cysteine 
TBST                        Tris-Buffered Saline and Tween 20 
TNF-α                       Tumor necrosis factor α 
V-ATPase                 Proton-pump vacuolar ATPase 


















1.1 Hydrogen sulfide (H2S) 
Hydrogen sulfide, also known as H2S, is a colorless and flammable gas with the 
characteristic foul odor of rotten eggs [1]. For hundreds of years, H2S has been 
known to be toxic.  H2S was, during this period, regarded as a potentially harmful 
gas found in swamps, sewers and produced as a byproduct of the petroleum 
industry. H2S forms a weak acid in aqueous solution, thus acting as a strong 
reducing agent. At 50 ppm, H2S irritates the eyes and respiratory tract, whereas 
500 ppm may lead to unconsciousness and death, mainly attributed to inhibition 
of cytochrome oxidase and a consequent block of oxidative phosphorylation [2]. 
This negative view of the harmful effects of H2S was challenged in more recent 
years by the discovery of endogenous H2S in mammals. In recent decades, 
accumulating evidence has recognized the importance of H2S in many biological 
systems, including the cardiovascular, inflammatory and nervous systems. As a 
consequence, H2S is now recognized as the third gasotransmitter following nitric 
oxide (NO) and carbon monoxide (CO) [1]. 
 
A timeline maps out the important landmarks in H2S research starting in 1982 
when Stipanuk and Beck first detected H2S production in liver and kidney tissues 
synthesized by cysthathionine-β-synthase (CBS) and cystathionine-γ-lyase (CSE) 
[3]. This was followed more than a decade later when Hideo Kimura presented 
evidence that endogenous H2S, synthesized by CBS in the brain, functions as a 





L-cysteine via CSE, relaxed blood vessels [4]. In 2001, Rui Wang and colleagues 
identified the opening of KATP channels as a main mechanism for H2S action [5]. 
Beyond, 2001, there have been in excess of 10,000 publications focused partly or 
entirely on the physiological and/or pathological functions of H2S in body 
systems. As a newly discovered gasotransmitter, H2S acts via specific molecular 
and cellular targets as well as showing several distinctive characteristic and 
specific functions at physiologically relevant concentrations [6]. 
 
1.2 Physical and chemical properties of H2S 
H2S is the sulfur analogue of water (H2O) with a molecular weight of 34.08. It is 
able to diffuse readily through plasma membranes without the need for specific 
membrane transporters [7]. H2S is a small molecule that is soluble in water (1 g in 
242 ml at 20°C), lipophilic solvents or organic solvents [8, 9]. It can be oxidized 
by a variety of agents to form sulfur dioxide (SO2), sulfates such as sulfuric acid 
and elemental sulfur [10]. In aqueous solution, it acts as a weak acid with a pKa 
of 6.76 at 37°C and dissociates as follows: H2S ↔HS-+ H+ ↔S2-+ 2H+. At 
physiological pH of 7.4, approximately one-fifth of the total sulfide exists as H2S 
while four-fifth exists as the hydrosulfide anion (HS-) [7].  
 
1.3 Biosynthesis of H2S 
The enzymes and the pathways that catalyze H2S production are referred to in 
Figure 1. H2S can be generated both enzymatically and non-enzymatically [11]. 
Enzymatically, H2S can be synthesized by at least four separate pathways [3, 12-





CSE forms thiocysteine from cystine, which then are able to rearrange to form 
H2S. (3) 3-mercaptopyruvate sulfurtransferase (MST) along with cysteine 
aminotransferase (CAT) form H2S from 3-mercaptopyruvate and (4) cysteine 
lyase (CL) converts L-cysteine and sulfite to H2S and L-cysteate. Alternatively, 
H2S can be synthesized from homocysteine, an intermediate product of 
methionine metabolism, but its reaction is only catalyzed by CBS. A minor 
pathway for the production of H2S is the non-enzymatic generation from 
thiosulfate, which is produced after sulfide oxidation [11].  
 
 
Figure. 1 The biosynthesis and degradation of H2S in mammalian cells.  
This figure is adapted from Li L, Rose P, Moore PK (2011). (Ann. Rev. 





1.4 Physiological functions of H2S 
Although H2S was first recognized as a toxic gas without any significant 
physiological function, recent studies have demonstrated that H2S plays an 
important role in both physiological and pathological conditions. These studies 
have contributed significantly to our understanding of the biological roles of H2S 
in the cardiovascular, neuronal, endocrine systems and in inflammation [12, 20-
23]. 
 
H2S is well known to function as a vasodilator and therefore H2S may be involved 
in the regulation of cardiovascular function [24]. Whiteman and Moore [18] 
suggested that H2S is able to promote blood flow through the microcirculation and 
to dilate both large capacitance blood vessels (e.g. aorta) and smaller resistance 
blood vessels. In some blood vessels H2S can also causes vasorelaxation [11] by 
inhibiting the formation of vascontrictor AGT II or by activating vascular smooth 
muscle KATP channels [5]. Moreover, Yang and colleagues suggested a 
physiological role for H2S synthesised by CSE in endothelial cells in blood 
pressure regulation [25]. Further animal studies have shown that deficiency of 
endogenous H2S contributes to hypertension [26] and increased infarct size after 
coronary artery occlusion, while H2S donors are protective in these conditions 
[27].  	  
H2S also plays an important role in brain function, probably acting as a 
neuromodulator as well as an intracellular messenger [22]. For example, in 





cAMP probably by direct activation of adenylyl cyclase and thus activates cAMP-
dependent processes. In astrocytes, H2S has possible physiological functions in 
augmenting long-term potentiation. Possible mechanisms include modulation of 
the activation of neuronal N-methyl-B-aspartate (NMDA) receptors, regulation of 
the redox status, maintenance of the excitatory/inhibitory balance in 
neurotransmission and scavenging of free radicals and reactive species thereby 
reducing oxidative damage [4, 17, 28, 29].  
  
Early research suggested that H2S exhibited both anti-inflammatory and pro-
inflammatory effects. For example, Whiteman and colleagues [7] suggested that 
H2S exhibits anti-inflammatory effects. This group reported that H2S donors 
reduce pro-inflammatory cytokine expression levels and decrease LPS-induced 
activation of NF-κB. However, Li and colleagues [21] noted that NaHS 
administration increases organ myeloperoxidase (MPO, a marker for neutrophil 
infiltration) activity in rats, which might suggest that H2S is pro-inflammatory. 
Recently, several publications have suggested that H2S is a mediator of the acute 
and/or chronic inflammatory response [30-34]. For example, in vitro, Han and 
colleagues [30] indicated that NaHS ameliorates tobacco smoke-induced 
emphysema in mice. Esechie and colleagues [31] found that NaHS protected the 
lung against the combined insult of burn and smoke inhalation. In a rat model of 
allergic asthma, NaHS was found to reduce airways inflammation [32].  Moreover, 
inhaled H2S reduced LPS-evoked septic shock [33]. Recently, Zhu and colleagues 





Treatment of ovariectomised rats with estrogen for 12 weeks has been shown not 
only upregulate CSE tissue expression and H2S production but also limited 
myocardial inflammation via reduced levels of IL-6 and TNF-α [34].  
 
Hence, an abundance of experimental evidence suggested that H2S has a 
prominent role in normal physiological functions and pathophysiological roles. As 
shown in Figure 2, H2S may act on many targets in different human diseases. 
Examples of H2S involvement in human diseases are in cancer [35], heart failure 
[36], organ transplant [37], peripheral artery disease [38], inflammatory bowel 
disease [39], Alzheimer’s disease [40], acute myocardial infarction (MI) [41], 
stroke [42], atherosclerosis [43], hypertension [44], erectile dysfunction [45], 
metabolic syndrome [46], diabetes [47], and thrombosis [48]. 
 
 
Figure 2. Therapeutic targets for H2S.   
This figure is adapted from Predomore BL, Lefer DJ, Gojon G (2012). (Antioxid 






1.5 H2S-donating compounds 
H2S is increasingly being thought of as a cytoprotective agent.  This gas is 
thought to restore physiological function in diseased cells or organ systems, and 
more recent work has focused on identifying novel H2S donors. To date, a number 
of such donors have been characterized. The naturally H2S occurring compounds 
include garlic [46, 49-51], sulforaphane and iberin [52-57]. The synthetic H2S 
donors include cysteine-activated H2S donors [58], cysteine analogs [59-66] such 
as S-propyl cysteine, S-allyl cysteine (SAC), S-propargyl cysteine (S-SPRC) and 
N-acetyl cysteine (NAC), H2S-releasing derivatives of non-steroidal anti-
inflammatory drugs (NSAID) [21, 23, 67-96], morpholin-4-ium 4 methoxyphenyl 
(morpholino) phosphinodithioate (GYY4137) [39, 97-100]; and, recently, a nitric 
oxide (NO) and H2S-releasing derivative of aspirin (NOSH-aspirin) [101, 102]. 
	  
1.5.1 Sulfide salts 
Sulfide salts, such as NaHS, Na2S and CaS, form HS- and H2S and dissolve 
immediately in physiological buffer with rapid increase in H2S concentration 
[103]. However, H2S released from these sulfide salts is rapidly lost from solution 
by volatilization in laboratory conditions [103], or transferred across respiratory 
membranes [104-106]. This somewhat limits their therapeutic potential.  	  






It has been known for a long time that garlic has antioxidant activity. Recently a 
number of researchers reported that the antioxidant effects of garlic are derived 
from H2S production. So far, allicin (diallyl thiosulfinate) is the best characterized 
naturally occurring H2S-donating compound from garlic (Allium sativum) [49]. 
Benavides and colleagues [50] measured H2S production in real time with a 
polarographic sensor, they observed that, in the presence of GSH and under 
anoxic conditions, red blood cells rapidly (within minutes) produced H2S from 
garlic extract and from two of the decomposition products of allicin, diallyl 
trisulfide (DATS; Fig. 3A) and diallyl disulfide (DADS). Moreover, H2S was 
produced in the presence of GSH by reduced thiols on the red blood cell 
membrane. Additional support for H2S production from garlic in vivo is that 
infusion of DADS (1 g/kg 1.8 mg/kg/min) in rats increased exhaled H2S. Garlic 
extracts (DATS and DADS) via H2S production can dilate the rat aorta [50] or can 
function as s anti-cancer [51] and anti-diabetes [46] agents although whether these 
effects are H2S-mediated or not is not known.  
1.5.2.2 Sulforaphane and erucin  
Sulforaphane (Figure 3B) is an isothiocyanate compound found in broccoli 
(Brassica oleracea). Humans are able to absorb rapidly sulforaphane [52]. Erucin 
(Figure 3C) is found in high levels in rocket salad species (Eruca sativa), it is also 
an isothiocyanate. These isothiocyanate compounds are metabolized to produce 
H2S [52]. Recent studies have found that sulforaphane protect vascular 
endothelial cells and smooth muscle cells from inflammatory and oxidative stress 





neuroprotective and anti-inflammatory actions and it provides some protection 
against serotonin-induced toxicity, hemorrhage and ischemia reperfusion injury 
[56, 57] but whether these effects are H2S mediated are not clear.  
 
1.5.3 Synthetic H2S donors 
1.5.3.1 Cysteine-activated H2S donors   
Based on the lability of nitrosothiol (S-N) bonds, Zhao and colleagues [58] 
developed a novel class of H2S donors. In their report the N-(benzoylthio) 
benzamide (Figure 3D)  moiety was able to release H2S slowly in the presence of 
excess L-cysteine. A peak of 25.4 µM H2S was observed 18 min after 40 µM of 
N-(Benzoylthio) benzamide was incubated with 4 mM cysteine. All of these 
compounds can dissolve in phosphate buffer, but in the absence of L-cysteine, 
none of them were able to generate H2S. 
1.5.3.2 Cysteine analogs 
Cysteine analogs have the ability to act as potential substrates for endogenous 
cysteine-metabolizing enzymes. Such compounds include S-allyl cysteine (SAC, 
also a derivative of garlic) (Figure 3E), S-propyl cysteine (SPC) (Figure 3E), S-
propargyl cysteine (SPRC) (Figure 3E) and N-acetyl cysteine (NAC) (Figure 3F). 
Wang and colleagues [59] used the methylene blue method to measure H2S 
production via homogenized rat cardiac ventricles. They noted H2S generation 





two-fold and the rate of H2S production increased as the terminal carbon of the 
molecule became progressively less saturated. Recent work has shown these 
cysteine analogs also regulate cardiovascular [59-61], neuromodulation [62], 
cancer [63] and inflammation [64-66] although, yet again, whether these effects 
are H2S-mediated remains to be determined conclusively. 
1.5.3.3 Dithiolethione and its NSAID chimeras 
A number of studies indicated that anethole dithiolethione (ADT) and its main 
metabolite (ADT-OH; 5-(4-hydroxyphenyl)-3H-1, 2-dithiole-3-thione) are H2S 
donors [67-73]. ADT-OH can also be modified prior to esterification, to form 
molecules such as ACS 5 (Figure 3G), ACS 48 (Figure 3H) and ASC 50 (Figure 
3I). Combined ADT-OH with a variety of compounds has frequently been shown 
to enhance their biological activity. This is seen especially in the case of the 
nonsteroidal anti-inflammatory drugs (NSAIDs) and has been used to help 
counter some of their adverse side effects [74]. Recent research has demonstrated 
that ADT-OH and its NSAID chimeras function in regulation of cardiovascular 
[68, 69, 71-73, 75, 76], had neuromodulation [70, 77, 78], anti-inflammatory [21, 
23, 79-85] as well as gastrointestinal sparing effects [86-91] . 
1.5.3.4 GYY4137 and analogs  
The release of H2S from GYY4137 (Figure 3J) was first reported in a paper 
authored by Li and colleagues [97]. They indicated that GYY4137 was able to 
slowly release H2S both in aqueous solution in vitro as well as after intravenous or 





colleagues [98] using methylene blue method found that incubation of GYY4137 
(400 µM) in cell culture medium containing human breast adenocarcinoma MCF-
7 cells led to the sustained generation of low (15–20 µM) concentrations of H2S 
for up to 7 days. GYY4137 has proved useful in the study of the many and varied 
biological effects of H2S. For example, in both acute (L-NAME-induced) and 
chronic (spontaneously hypertensive) hypertension rat model, GYY4137 
displayed both vasodilator and antihypertensive activity [97]. Li and colleagues 
also reported that GYY4137 reduced LPS-evoked septic shock [99] and reduced 
knee joint oedema due to an intra-articular injection of Freund’s adjuvant [100]. 
Whiteman and colleagues demonstrated that GYY4137 also protected against 
endotoxic shock in rats [39]. GYY4137 inhibited tumor necrosis factor-α, IL-6 
and interleukin (IL)-1β production and reduced NF-κB activation, 
cyclooxygenase-2 and iNOS expression, as well as NO and prostaglandin E2 
generation [30]. Moreover, anti-cancer effects of GYY4137 have been observed 



















Figure 3.  Chemical structures of H2S-releasing compounds. 
These structures are adapted from Kashfi K, Olson KR (2013). (Biochemical 
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1.5.4 NO and H2S releasing aspirin (NOSH-aspirin) 
The NOSH-compounds including NOSH-1 (4-(3-thioxo-3H-1,2-dithiol-5-yl) 
phenyl 2-((4-(nitrooxy)-butanoyl)oxy) benzoate); NOSH-2 (4-(nitrooxy)butyl (2-
((4-(3-thioxo-3H-1,2-dithiol-5-yl)phenoxy)carbonyl)phenyl)); NOSH-3 (4-
carbamothioylphenyl 2-((4-(nitrooxy)butanoyl)-oxy)benzoate); and NOSH-4 (4-
(nitrooxy)butyl 2-(5-((R)-1,2-dithiolan-3-yl)pentanoyloxy)-benzoate) are shown 
in the Figure 4. They were designed to release both H2S and NO [101]. Kodela 
and colleagues [101] indicated that NOSH-1 (NOSH-aspirin, NBS-1120) is able 
to release H2S in vivo. Besides, using the methylene blue method, Chattopadhyay 
and colleagues [102] showed that NOSH-aspirin released H2S in vitro.  NOSH-
aspirin was shown to have anti-inflammatory [102] and anti-cancer [101, 102] 
properties both in vivo and in vitro. However, to date only a series of compounds 
based on aspirin have been reported. How other NOSH-NSAIDs behave has yet 
to be reported.  
 
Figure 4.  Chemical structures of NO and H2S releasing aspirin. 
These structures are adapted from Kashfi K, Olson KR (2013). (Biochemical 





1.6 Roles of H2S in cancer  
As shown in Figure 5, H2S possesses differential anti-cancer effects [107]. H2S 
donors have been reported to play a potentially important role in anti-cancer 
treatment. For instance, SPRC produced a concentration dependent inhibition of 
growth of cultured human gastric cancer cells (SGC-7901) [63]. This report 
indicated that SPRC (1 µM) caused 18% inhibition of viability and suppressed 
colony forming and migration ability, as well as significantly increased H2S 
concentration in culture media and CSE protein expression. SPRC stimulated 
apoptosis, and induced cell cycle arrest at the G1/S phase. SPRC also increased 
Bax and p53 but not Bcl-2 protein and mRNA expression [63]. Moreover 
Chattopadhyay and colleagues [94] pointed out that HS-aspirin preferentially 
killed estrogen receptor (ER)-negative breast cancer cells compared with the 
normal epithelial mammary cell line. 
 
Figure 5.  “Direct” anticancer effects of H2S.  
This figure is adapted from Predmore BL, Lefer DJ, Gojon G (2012).  (Antioxid 






All of these effects on cancer cells showed that H2S donors play an important role 
in anti-cancer treatment, but at the same time, whether these H2S donors had any 
effect on survivability of normal cells, which would be very important for cancer 
therapy is still unknown.  Our group recently found that the slow-releasing H2S 
donor (GYY4137) kills cancer cells without affecting the growth of normal cells 
[98]. In this report, GYY4137 (800 µM) killed 90–97% of 5 different cancer cells 
over 5 days. i.e. human breast cancer (MCF-7), human cervical carcinoma (HeLa), 
human osteosarcoma (U2OS), human hepatocellular carcinoma (Hep-G2), 
colorectal carcinoma (HCT-116), but did not affect the survival of non-cancer 
human diploid lung fibroblasts (IMR90 and WI38). The apparent IC50 for 
GYY4137 in MCF-7, MV4-11 and HL60 cells was approx 350 µmol/l. This study 
also suggested that GYY4137 killed MCF-7 cancer cells by promoting apoptosis 
via presence of cleaved caspase 9 and cleaved PARP and triggered cell-cycle 
arrest in the G2/M phase, but it did not affect non-cancer IMR90 cells. In an vivo 
(mouse xeonograft) study injection of HL-60 or MV4-11 cancer cells into 
immunodeficient mice followed by daily i.p. injection of GYY4137 (100, 200 and 
300 mg/kg) for 14 days, revealed a dose-dependent decreased in the growth of 
HL-60 and MV4-11 tumors [98]. In addition, Yu and colleagues [108] indicated 
GYY4137 (2 mmol/l) did not affect viability of non-tumorigenic HepG2 cells. All 
of these results suggested that GYY4137 might be a very useful H2S donor 
compound for cancer therapy. The mechanism by which GYY4137 kills cancer 






Figure 6.  Schematic representation of the differences between oxidative 
phosphorylation, anaerobic glycolysis, and aerobic glycolysis (Warburg 
effect). 
This figure is adapted from Vander Heiden MG, Cantley LC, Thompson CB 
(2009).  (Science. 2009 May 22;324(5930):1029-33.) 
 
Cancer cells are highly proliferative. Vander Heiden and colleagues [109] 
summarized the difference between tumor, proliferative tissue, and differentiated 
tissue in glycolysis in Figure 6. Warburg and colleagues [110] observed that 
cancer cells exhibit altered metabolism which is marked by elevated glycolysis 
and increased glucose utilization, cancer cells tend to convert most glucose to 
lactate regardless of whether oxygen is present (aerobic glycolysis) [109]. 
Thereby, Hamanaka and colleague indicated targeting glucose metabolism may 
provide a selective mechanism by which to kill cancer cells in Figure 7 [111]. 
Many recent papers indicated some enzymes that regulated glycolysis as the 





[112, 113], hexokinases (HKs) [114, 115], LDH-A [116, 117], PKM2 [118, 119]. 
Therefore, if a drug can be developed which is able to interfere one activity or 
expression of one or more of these enzymes involved in the glycolysis, then such 
a drug might have capability as an anti-cancer therapy. 





Figure 7. Potential targets for cancer therapy found within metabolic 
pathways involved in glycolysis. 
This figure is adapted from Hamanaka RB, Chandel NS. (2013). (J Exp Med. 
2012 Feb 13; 209(2):211-5.) 
 






Physiological pHi is associated with many cellular processes such as metabolism 
[120], the cell cycle [121-131] and cell proliferation [123, 124]. Moreover, most 
mammalian cells in tissue culture will not proliferate at a pH less than 6.6; 
therefore, cells need to maintain their pHi within the normal physiological range 
(pH 7.2–7.4)  [123]. Thus, regulation of pHi is required for the maintenance of an 
environment appropriate for cellular activities. Because of cancer cells exhibit 
enhanced glucose uptake and utilization, in order to recycle NAD+ that is used in 
the glycolysis pathway in cancer, the pyruvate which is generated is channeled 
into anaerobic respiration thence resulting in high lactate production [125]. As an 
organic acid, lactate accumulation triggers a decrease in intracellular pH (pHi) in 
cancer cells. To compensate for such intracellular acidification, cancer cells 
overexpress a range of proteins, mostly transmembrane-localized, that are 
involved in regulating pH. These include monocarboxylate transporters (MCTs) 
[126], proton-pump vacuolar ATPase (V-ATPase) [127], carbonic anhydrases 
(CAs) [128], anion exchangers (AEs) [129] and sodium/proton exchangers (NHEs) 
[130].  
  
McCarty and colleagues [131] indicated four distinct strategies (Figure 8) for 
manipulation of the extracellular (pHe) and/or pHi of tumors in cancer therapy. 
These including, (a) alkalizer therapy: to increases the pH of the extracellular 
space. (b) proton pump inhibition: to decreases the intracellular pH, while 
increasing the extracellular pH. (c) acute intracellular acidification therapy: to kill 





extracellular acidification therapy: to enable tumor-selective release of cytotoxic 
drugs encased in pH-sensitive nanoparticles.  
 
Therefore, if a drug were able to change the pH of cancer cells thereby resulting 
in the demise of the cancer cells alone, it would have a promising role as a 
therapeutic anti-cancer therapy.  
 
        
 
Figure 8. Therapeutic Strategies for Manipulating Tumor pH.  
This figure is adapted from McCarty MF, Whitaker J. (2010). (Altern Med 
Rev. 2010 Sep;15(3):264-72.) 
 
Recently, Lee and colleagues [132] indicated that reducing the intracellular pH of 
cancer cells promoted cancer cells apoptosis. In this report, GYY4137 increased 







GYY4137 was able to impair the activity of pH regulator molecules (i.e. AEs and 
NHEs) in cancer cells, resulting in intracellular acidification that further promoted 
the H2S killing effect. As mentioned above, interfering glycolysis or intracellular 
in cancer cells is the strategy for cancer therapy. H2S released from GYY4137 not 
only increase glycolysis in cancer cells, but is also involved in the intracellular 
acidification of cancer cell, thus if we take into account all of these effects it 
would highlight the possible mechanism of H2S donors in cancer therapy. 
 
1.7 Research objectives  
H2S is a gasotransmitter, which has recently been shown to act as a potential anti-
cancer agent. There is growing interest in H2S donors for studying different 
physiological functions and as potential therapeutics GYY4137 is one of the most 
widely reported slow-releasing H2S donors.  When GYY4137 is used in cancer 
and non-cancer (normal) cells it exhibits selective anti-survival activity for cancer 
cells but not normal cells. Thus GYY4137 and its analogues are attractive 
potential agents for cancer therapy. 
 
The present study aims to identify the biological profile of a novel slow-releasing 
H2S donor, FW1010 (GYY4137 analogue) in terms of its potential anti-cancer 
properties in cancer and normal cells culture models with that of GYY4137. In 
addition, we also sought to elucidate the mechanisms involved in the anti-cancer 






2. Materials and Methods 
2.1 Cell culture 
 Human diploid cell (WI38) line, human breast cancer cell lines (MCF-7 and 
MDA-MB-231), human liver hepatocellular cell (HepG2) and human 
osteosarcoma (U2OS) cell line were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% v/v fetal calf serum (FBS) containing 
penicillin/streptomycin (100 U/ml) and L-glutamine (2 mM). The cell lines were 
housed in an incubator (37°C, 5% CO2/95% air). 
 
2.2 Measurement of H2S 
The profile of H2S release from GYY4137, FW1010 was assessed by the classical 
methylene blue spectrophotometric assay [133] for a period of 6 days. MCF-7 
cells were seeded in 12-well plates. After 24 hours, GYY4137 or FW1010 (200, 
400, 800 µM) was added to the culture medium and plates incubated for a further 
6 days. During the incubation period, 100 µL of supernatant medium was 
removed from wells in the 12-well plate into a 96-well plate and H2S 
concentration determined after addition of 100 µl zinc acetate (ZnAc, 0.85% 
w/v/3% w/v NaOH mixture, 1:1 ratio), 20 mM N, N-dimethyl-p 
phenylenediaminedihydrochloride (NNDPD) and 28 mM FeCl3 (final 
concentrations of NNDPD and FeCl3, 2.5 mM and 3.3 mM respectively). Samples 
were then centrifuged (13,000 rpm, room temperature, 3 minutes). The presence 
of H2S was indicated by a blue colour. Absorbance of the samples was determined 





conducted using serial dilutions of sodium hydrogen sulphide (NaHS, 6.125, 12.5 
25, 50, 100, 200, 400, 800 µM) incubated for 30 minutes, developed using 
NNDPD reaction as above and the absorbance read at 670 nm. The concentration 
of H2S in the culture medium was determined against the NaHS standard curve. 
 
2.3 Drug treatment 
NaHS was purchased from Sigma. GYY4137 and FW1010 were synthesized in 
house by A/Prof Brian William Dymock’s laboratory (Department of Pharmacy, 
National University of Singapore). All drugs were diluted in DMEM medium to 
the final concentration (200, 400, 600, 800 µM). The non-treatment group (NT) 
was the control group. 
 
2.4 Cell viability analysis 
Each cell line was incubated with either NaHS, GYY4137 or FW1010 (200, 400 
or 800 µM) for a period of 5 days. Cell lines were cultured in 12-well plates. At 
the end of the treatment, cells were dissociated with 0.25% w/vtrypsin-EDTA (5 
mM KCl, 0.4 mM KH2PO4, 4 mM NaHCO3, 137 mM NaCl, 0.3 mM Na2HPO4-
7H2O, 5.6 mM Dextrose, 0.025 mM Phenol Red, 0.9 mM Na2-EDTA, 0.1 mM 
trypsin). Cells were then re-suspended in 1 mL fresh DMEM medium and further 
incubated with 0.4% (w/v) trypan blue dye for 3 min. Viable cells stained blue 
and the ratio of stained cells/total cells was determined using a hemocytometer 





as the ratio of stained cells against total cells. All cell viability curves are fitted to 
a maximum of 100% using Origin Software, Pharmacology does-response curve. 	  	  
 
2.5 Western blot analysis 
Cells were washed with ice-cold PBS buffer (137 mM NaCl, 2.7 mM KCl, 10 
mM Na2HPO4 • 2 H2O, 2 mM KH2PO4, pH 7.4) and homogenized with lysis 
buffer (125 mM NaCl, 25 mM Tris pH 7.5, 5 mM EDTA, 1% m/v NP-40, 1 mM 
NaF, 2 mM Na3VO4 and protease inhibitor cocktail tablet).  Cell lysates were then 
vigorously shaken on ice for one hour and centrifuged (13,200 g, 4°C, 10 min). 
The supernatant was collected and denatured using SDS-sample buffer (50 mM 
Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 1% β-mercaptoethanol, 12.5 mM 
EDTA, and 0.02% bromophenol blue) and the epitopes were exposed by boiling 
the protein samples in a dry block heater at 100°C for 10 min. A 12% w/v SDS-
PAGE gel was used to load equal amounts of proteins into each well and the 
polyvinylidene difluoride (PVDF) membrane was used to transfer. The membrane 
was then blocked using 10% v/v milk/TBST buffer for one hour and incubated 
with primary antibodies, cleaved PARP (1:2000) and monoclonal anti-β-actin 
(1:20000), at 4°C overnight. Membranes were then washed with PBS/0.1% v/v 
Tween 20 for 3 times and incubated with secondary antibodies (goat anti-rabbit 
IgG, 1:5000) and goat anti-mouse IgG, 1:5000) at room temperature for 1 hour. 
Finally, antibody-reactive bands were detected with LuminataTM Crescendo 
Western HRP Substrate and the density of the bands developed on film was 





2.6 Measurement of intracellular pH (pHi) 
Intracellular pH (pHi) of cells was measured by a ratiometric analysis method 
using confocal microscopy (Zeiss) [134, 135]. A pHi sensitive fluorescent probe 
BECEF (2′,7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein–acetoxymethyl) 
was used to measure  pHi. After 5 days of treatment, culture media containing 
cells (MCF-7 and WI38 cells) was aspirated and washed with mammalian 
Ringer’s solution (2.2 mM CaCl2, 5.6 mM KCl, 154 mM NaCl, 2.4 mM NaHCO, 
3, 2 mM Tris-Cl, pH 7.4). The cells were then incubated with 2 µM BCECF probe 
in mammalian Ringer’s solution for 10 minutes (37°C, 5% CO2 in air). Excess 
dye was removed and the cells were washed once with mammalian Ringer’s 
solution. Cells were then incubated in mammalian Ringer’s solution prior to 
imaging byconfocal microscopy. A fluorescence signal was obtained at pH-
insensitive and pH-sensitive wavelengths of 405 and 488 nm respectively and the 
emission wavelength intensity was measured at 500 nm. The entire cell area was 
selected for pHi measurement. The ratio of signals obtained at 488/405 nm 
corresponded to the pHi. For the calibration curve, use the nigericin/high-
potassium method [136]. Nigericin is strongly pH-buffered high concentration K+ 
solutions of known pH values, it can break down the pH gradient across the 
plasma membrane and equilibrate pHi with pHe [136]. Measurement of the 
fluorescence ratio data at three different pH values (i.e. pH 6.5, pH 7.0 and pH 7.5) 
in the presence of 10 µM nigericin (Sigma) in buffer comprising 125 mM KCl, 1 






2.7 Measurement of glucose consumption by cells 
Glucose amount was determined using a Glucose Colorimetric Assay Kit 
(BioVision K606). MCF-7 and WI38 cells were treated with GYY4137 or 
FW1010 (200, 400, 800 µM) for a period of 5 days. Control groups lacked cells.  
At the end of the treatment, culture medium from each group was collected and 
centrifuged (10,000 g, 4°C, 10 min), to isolate supernatant which was then stored 
at -80°C. Samples were thawed and diluted 25 fold. 50 µl of diluted sample was 
added to 96-well plates and incubated with 50 µl Glucose Reaction Mix reagent 
comprising 46 µl Glucose Assay Buffer, 2 µl Glucose Probe and 2 µl Glucose 
Enzyme Mix in the kit for the reaction to take place at 37°C (30 minutes). 
Absorbance was monitored at 570 nm. The glucose standard curve was plotted 
using the glucose standard prepared in serial dilution concentrations of 0, 2, 4, 6, 
8, 10 nmol/well and developed with the Glucose Reaction Mix reagent as above. 
At the end of the experiment, cells were lysed with RIPA lysis buffer and protein 
concentration was determined using the Bradford assay (Bio-Rad 500-0205). 
Glucose amount was normalized to protein concentration. 
 
The amount of glucose detected in control groups represents the total amount of 
glucose present in culture medium. Over 5 days of incubation, consumption of 
glucose by cells is expected. Thus, by subtracting the amount of glucose left in 
supernatant of tests groups from the control groups, the degree of glucose 





consumed by cells = amount of glucose in supernatant of control group – amount 
of glucose in supernatant of test groups.         
 
2.8 Measurement of lactate production by cells  
Lactate amount was determined using a Lactate Colorimetric Assay Kit 
(BioVision K607). MCF-7 and WI38 cells were treated with GYY4137 or 
FW1010 (200, 400, 800 µM) for a period of 5 days. Control groups lacked cells.  
At the end of the treatment, culture medium from each group was collected and 
centrifuged (10,000 g, 4°C, 10 min),  to isolate supernatant which was then stored 
at -80°C. Samples were thawed and diluted 10 fold. 50 µl of diluted sample was 
added to 96-well plates and incubated with 50 µl Lactate Reaction Mix reagent 
comprising 46 µl Lactate Assay Buffer, 2 µl Lactate Probe and 2 µl Lactate 
Enzyme Mix in the kit for the reaction to take place at 37 °C (30 minutes). 
Absorbance was monitored at 570 nm. The lactate standard curve was plotted 
using the lactate standard prepared in serial dilution concentrations of 0, 2, 4, 6, 8, 
10 nmol/well and developed with the Lactate Reaction Mix reagent as above. At 
the end of the experiment, cells were lysed with RIPA lysis buffer. Protein 
concentration was determined using the Bradford protein assay (Bio-Rad 500-
0205). Lactate amount was normalized to protein concentration. 
 
The amount of lactate detected in control groups represents the baseline amount 
of lactate present in culture medium. Over 5 days of incubation, lactate produced 





control groups from the tests groups, the degree of lactate produced by cells can 
be determined. In other words, amount of lactate produced by cells= amount of 
lactate in supernatant of test groups – amount of lactate in supernatant of control 
group. 
 
2.9 Statistical analysis 
Data shown mean ± standard deviation (s.d.). Comparisons are between non-
treated (NT) and treatment groups, FW1010 treatment group and the GYY4137 
treatment group. Statistical significance was analyzed using Student’s t-test. A p 
value of less than 0.05 was considered significant. 
 
2.10. Lists of reagents, cell lines, antibodies and instruments. 
2.10.1 Reagents 
1. Dulbecco’s modified Eagle’s medium (DMEM) (Biowest, France). 
2. Trypsin EDTA, L-glutamine, fetal bovine serum and Pencillin–
Streptomycin Solution (Gibco® by Life Technologies,	  Singapore). 
3. Trypan blue (Sigma Aldrich, Singapore). 
4. LuminataTM Crescendo Western HRP Substrate (Millipore, Singapore). 
5. Protease inhibitor cocktail tablet (Roche Diagnostics, Singapore). 
6. (2′,7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein–acetoxymethyl) 
(BCECF) (Invitrogen, Singapore). 
7. Glucose & lactate colorimetric assay kits (BioVision). 





9. NaHS (Sigma Aldrich, Singapore). 
10. Nigericin (Sigma Aldrich, Singapore). 
11. GYY4137 and FW1010 were synthesized in house by A/Prof Brian 
William Dymock’s laboratory (Department of Pharmacy, National 
University of Singapore). 
 
2.10.2 Cell lines 
All cell lines were obtained from the American Type Culture Collection (ATCC). 
Normal cell line: WI38 human diploid lung fibroblast cell line 
Cancer cell lines: MCF-7 human breast cancer cell line, MDA-MB-231 human 
breast cancer cell line, HepG2 human liver hepatocellular cell line and 
U2OS human osteosarcoma cell line. 
 
2.10.3 Antibodies 
1. Cleaved PARP (Asp214) Antibody (Human Specific) was purchased from 
Cell Signaling Technology. 
2. Monoclonal anti-β-actin, clone AC-15 was purchased from Sigma 
Chemical Company. 
3. Immunopure Peroxidase Conjugated Goat Anti- Rabbit IgG (H+L) was 
purchased from Thermo Scientific Pierce.  
4. Immunopure Peroxidase Conjugated Goat Anti-Mouse IgG (H+L) was 






2.10.4 Experimental instruments 
1. CO2 Water Jacketed Incubator (Forma Binder, USA). 
2. Biological safety cabinets BSC4-3 (Nuaire, USA). 
3. Eppendorf centrifuge 5810R (VWR, Singapore).  
4. Phase contrast & confocal microscope (Zeiss, Singapore). 
5. Stuart orbital shaking platform (Sciencewerck, Singapore).  
6. Heidolph Titramax microplate shaker (Sciencewerck, Singapore).  
7. Dry block heater Wise Therm Company (Sciencewerck, Singapore). 
8. Finepcr	  vortex mixer (Insta BioAnalytik, Singapore). 
9. SRX-101A film processor (Konica Minolta Medical and Graphic Inc). 
10. Tecan multimode reader Infinite 200 PRO (Tecan Asia Pacific Pte Ltd 
Singapore). 
11. Yihud Water bath (Insta BioAnalytik Pte Ltd).  
















3.1 H2S releasing of FW1010 and GYY4137. 
In preliminary screening tests, we identified a potential, H2S slow-releasing donor 
referred to hereafter as FW1010. This compound is based on the chemical 
structure of GYY4137. The structure of FW1010 is shown in Figure 9. The H2S-
releasing profiles of these two compounds were analyzed using the methylene 
blue spectrophotometric assay to detect released H2S. For this experiment, since 
we wished to monitor H2S release, either GYY4137 or FW1010 (200 - 800 µM) 
were incubated in DMEM medium containing MCF-7 cells up to 6 days (37°C, 5% 
CO2/95% air).  
 
 H2S released from either GYY4137 or FW1010 was sustained and concentration-
dependent over the 6 days period. As show in Figure 10, FW1010 released more 
H2S than did GYY4137 under the same experimental condition and at 
concentrations of 200 µM (Figure 10A), 400 µM (Figure 10B), and 800 µM 
(Figure 10C).  These results suggest that FW1010 is a novel H2S slow-releasing 
donor and moreover that it releases more H2S than does GYY4137 over the 6 
days incubation period.  
 





                                           (A) 
 
 
         (B)                                                           (C)                                                                           
 
 
Figure 10. Releasing of H2S from FW1010 and GYY4137  
Concentration of H2S was assessed spectrophotometrically using methylene blue 
spectrophotometric assay at λ=670 nm. Results showed H2S concentration in µM. 
(A) H2S releasing profile of GYY4137 and FW110 (200 µM).  (B) H2S releasing 
profile of GYY4137 and FW1010 (400 µM).  (C) H2S releasing profile of 
GYY4137 and FW1010 (800 µM). Results show mean +/- s.e. mean, n = 3 (i.e. 















3.2 Cell viability of NaHS, GYY4137 and FW1010 in different cell lines. 
The cell viability of a normal (i.e. non-cancer) WI38 human 
diploid lung fibroblast cell line and a range of cancer cell lines i.e. MCF-7 and 
MDA-MB-231 (human breast adenocarcinoma cell line), HepG2 (human liver 
hepatocellular cell line) and U2OS (human osteosarcoma cell line) were 
determined microscopically using trypan blue after incubation with NaHS, 
GYY4137 or FW1010 (200 - 800 µM) for a period of 5 days.  
 
NaHS, GYY4137 and FW1010 (200 - 800 µM) did not affect cell death in normal 
WI38 cells (Figure 11A). However, both GYY4137 and FW1010 (200 - 800 µM) 
(but not NaHS) caused concentration-dependent killing effect in all tested human 
cancer cell lines i.e. MCF-7 (Figure 11B), MDA-MB-231 (Figure 11C), HepG2 
(Figure 11D), U2OS (Figure 11E).  
 
The half maximal inhibitory concentration (IC50) is a measure of the effectiveness 
of a compound in inhibiting a specific biological or biochemical function.  The 
IC50 of FW1010 or GYY4137 was calculated in different cancer cells. In MCF-7 
cells, the IC50 of GYY4137 was 328 µM and the IC50 of FW1010 was 237 µM. In 
MDA-MB-231 cells, the IC50 of GYY4137 in this cell was 563 µM while the 
FW1010 had an IC50 of 284 µM. In HepG2 liver cells, the	  IC50 of GYY4137 was 
497 µM while the	  IC50 of FW1010 was 282 µM. In U2OS cancer cells the IC50 of 






Thus results show that, at a concentration of 400 µM, FW1010 exhibited a greater 
killing effect on several human cancer cell lines (MCF-7, MDA-MB-231, HepG2, 
U2OS) than did GYY4137 (Figure 12A).  Moreover, FW1010 (800 µM) also 
caused greater concentration-dependent killing effect of several human cancer cell 
lines (MCF-7, MDA-MB-231, HepG2) than did GYY4137 (Figure 12B).  
Intriguingly, neither GYY4137 nor FW1010 affected cell death in normal cells 
(WI38). NaHS (400 and 800 µM) did not significantly affect cell viability in all 
the tested cells. 
 
Thus, FW1010 was more effective potency in killing cancer cells than was 
GYY4137 at the same concentration. This may be related to the ability of 
FW1010 to release more H2S than GYY4137 at the same concentration. This 
killing effect was not observed in a normal cell line. Furthermore, NaHS which 
releases H2S rapidly killed neither cancer nor normal cells at the concentrations 
used in this experiment.  
 
Based on our observation, MDA-MB-231 is more resistant than MCF-7 cancer 
cells to killing by GYY4137. We propose that this reflects a difference in the 
inherent significantly of MDA-MB-231 cells to H2S. This rationales of this cell 
specific is different to H2S is not known. 
 





From the accumulated data, it is clear that both GYY4137 and FW1010 kill 
cancer cells. However it is not clear whether such cell death is brought about by 
apoptosis. Since cleavage of PARP facilitates cellular disassembly and serves as a 
marker in cells undergoing apoptosis [137, 138]; we investigated the possibility 
that FW1010 and GYY4137 trigger cancer cell death through apoptosis. To this 
end we examined the expression of cleaved-PARP protein using β-actin as the 
loading control. 
 
MCF-7 cells were treated with GYY4137 or FW1010 (200 - 800 µM) for 5 days 
and cleaved-PARP was measured by western blot analysis. The non-treatment 
group (NT) was the control. A strong concentration-dependent signal for cleaved-
PARP was detected in MCF-7 samples treated with either GYY4137 or FW1010 
(Figure 13A). FW1010 significantly increased cleaved-PARP protein intensity at 
the same concentrations of 400 µM and 800 µM (Figure 13B). 
 
These results suggest that both FW1010 and GYY4137 kill cancer cells likely by 










Figure 11. GYY4137, FW1010 but not NaHS significantly affected cancer cell 
viability but not the viability of normal cells (A).  
Concentration-response curves show the effect of NaHS, GYY4137, FW1010 and 
NaHS (200 - 800 µM) treatment for 5 days on cell viability of WI38 cell line (A); 
MCF-7 cell line (B); MDA-MB-231 cell line (C); HepG2 cell line (D); U2OS cell 
line (E). All results show mean +/- s.e. mean, n = 3 (i.e. experiments using 3 
different batches of cells). All curves are fitted to a maximum of 100% using 











Figure 12. GYY4137, FW1010 but not NaHS significantly affected cancer cell 
viability but not the viability of normal cells (B). 
The cell viability of different cancer and normal cells treated with NaHS, 
GYY4137 and FW1010 at 400 µM (A) or 800 µM (B). All results showed 
percentage cell viability of non-treatment (NT) incubated in the absence of drug 
and are mean +/- s.e. mean, n = 3, (i.e. experiments using 3 different batches of 












Figure 13. Western blot analysis of apoptosis marker (cleaved-PARP). 
(A) MCF-7 cells were treated GYY4137 or FW1010 (200 - 800 µM) for 5 days. 
Analysis of cleaved-PARP protein intensity NT was non-treatment group. β-actin 
was used as a loading control. (B) The density of the bands developed on film was 
quantified by Image J software. FW1010 compared to GYY4137 (# P<0.05, ## 
P<0.01). Results show mean +/- s.e. mean, n = 3 (i.e. experiments using 3 









3.4 Glucose consumption by cells of either FW1010 or GYY4137 treatment.  
In subsequent experiments we further investigated the mechanism by which the 
slow releasing H2S donors (FW1010 and GYY4137) killed cancer (but not normal) 
cells. Since cancer cells are highly dependent for metabolic energy on the 
availability of glucose [139-141] we hypothesized that H2S, released from 
FW1010 and GYY4137, may interfere with glucose metabolism and hence drive 
cancer cell death. To	  examine	  this	  possibility,	  glucose consumption in both cancer 
(MCF-7) and normal (WI38) cells was measured using Glucose Colorimetric 
Assay Kits.  
 
After treatment of MCF-7 or WI38 cells with GYY4137 or FW1010 (200 – 800 
µM) for 5 days we noted that both compounds significantly increased glucose 
consumption by MCF-7 cancer cells (Figure 14A) but not by WI38 normal cells 
(Figure 14B). This effect occurred in a concentration-dependent manner in the 
cancer cells.  
 
Taken together, these results suggest that slow-releasing H2S donors increase 
glucose consumption in cancer cells but not normal cells. FW1010 was more 
potent than GYY4137 in this regard. Thus, increased glucose consumption in 
cancer cells might underlie the mechanism by which FW1010 and GYY4137 
trigger cancer cell death. Under the same condition, FW1010 released more H2S 
than GYY4137 (Figure 10), which, in turn, increased glucose consumption by 





metabolism. This chain of events might promote glycolysis in cancer cells and 





Figure 14. GYY4137 and FW1010 increased glucose consumption in a 
concentration dependent manner in MCF-7 (but not in W138) cells.  
The effect of treatment (5 days) of a cancer (MCF-7) and a normal (WI38) cells 
with GYY4137 and FW1010 (200 – 800 µM) were as glucose colorimetric assay 
results. Glucose consumption by MCF-7 cells (A), glucose consumption by WI38 
cells (B). Results show mean +/- s.e. mean, n = 3, (i.e. triplicates). NT set as Non-
treatment group, GYY4137 compared to its NT (*P<0.01); FW1010 compared to 





3.5 Lactate production by cells of either FW1010 or GYY4137 treatment.  
Lactate is the end product of glycolysis [125] and hence lactate production is an 
additional indicator of the rate of glycolysis. Therefore, we measured lactate 
production in both a cancer cell line (MCF-7) and a normal cell line (WI38) using 
the Lactate Colorimetric Assay Kits.  
 
After treatment of MCF-7 and WI38 cells with GYY4137 or FW1010 (200 - 
800µM) for 5 days, GYY4137 and FW1010 significantly increased lactate 
production in a concentration dependent manner in MCF-7 cancer cells (Figure 
15A) but not in W138 cells (Figure 15B) which suggest that H2S enhanced lactate 
production in cancer cells more effectively after FW1010 treatment than after 
GYY4137 treatment under the same experiment conditions.  
 
Evidence suggests that cancer cells, exposed to the slow-releasing H2S donor, 
FW1010, over a prolonged period, exhibited higher glucose consumption, which, 
in turn, triggers enhanced glycolysis. FW1010 was more effective than GYY4137 
in this regard. Moreover, the higher glycolytic rate resulted in a drastic rise in the 
production of metabolic acid lactate in FW1010 treated cells compared with 
GYY4137 treated cells. However, this effect was prominent only in cancer cells, 
since normal cells that exhibited basal glycolytic rate and usually harvest energy 
through oxidative phosphorylation [140], the glycolysis and metabolic acid lactate 











Figure 15. GYY4137 and FW1010 increased lactate production in a 
concentration dependent manner in MCF-7 (but not in W138) cells.  
The effect of treatment (5 days) of a cancer (MCF-7) and a normal (WI38) cells 
with GYY4137 and FW1010 (200 – 800 µM) were as lactate colorimetric assay 
results. Lactate production by MCF-7 cells (A), Lactate production by WI38 cells 
(B). Results show mean +/- s.e. mean, n = 3, (i.e. triplicates). NT set as Non-
treatment group, GYY4137 compared to its NT (*P<0.01); FW1010 compared to 





3.6 Intracellular pH of FW1010 and GYY4137 in normal and cancer cell line. 
After treatment with FW1010 and GYY4137, cancer (but not normal) cells 
showed increased glycolysis as indicated by both glucose consumption and lactate 
production. Thus, we decided to examine whether such an enhancement of cell 
metabolic acid production might contribute to a decrease in intracellular pH (pHi) 
in cancer cells. To assess this possibility, ratiometric pHi was measured using 
BCECF dye by confocal microscopy imaging. In this assay a neutral cell 
(approximate pH 7.4) appears green in color whilst a cell with reduced pHi 
appears yellow (Figure 16A). 
 
After 5 days of treatment of MCF-7 cancer and WI38 normal cells with either 
FW1010 or GYY4137 (200 - 800µM) it was noted that FW1010 caused a 
significant concentration-dependent decline in pHi in MCF-7 cells. This effect 
was greater than that seen with GYY4137 at identical concentrations in the same 
cell line. Neither FW1010 nor GYY4137 affected pHi in normal WI38 cells 
(Figure 16B). 
 
Thus, prolonged exposure to low levels of H2S caused intracellular acidification 
in cancer (but not normal) cells. H2S, released from FW1010, caused greater 
intracellular acidification in cancer cells compared with GYY4137. The decline in 
pHi observed results in increased metabolic acid lactate greater due to enhanced 
glycolysis. The significant effect on pHi might lead to more cancer cells death 





H2S than GYY4137 given the same condition, this might have enhanced its 















Figure 16. Intracellular acidification upon H2S exposure to MCF-7 cancer 
cell line but not to WI38 normal cell line.  
(A) The effect of treatment (5 days) on cancer (MCF-7) and normal (WI38) cells 
with GYY4137 and FW1010 (200 - 800 µM) as confocal image results. (B) 
Results show pHi decreased by GYY4137 and FW1010 in a dose-dependent in 
cancer cells but not normal cells, and the decrease pHi of non-treatment (NT) are 
mean +/- s.e. mean, n = 3, (i.e. experiments using 3 different batches of cells). NT 
set as Non-treatment group, GYY4137 compared to its NT (*P<0.01); FW1010 







This study aims to identify a novel slow-releasing H2S donor (FW1010) and 
compare its biological profile in terms of anti-cancer ability in vitro with those of 
a known slow-releasing H2S donor, GYY4137. In addition, we sought to elucidate 
the mechanisms involved in the anti-cancer effect of both FW1010 and GYY4137 
in vitro.  
 
Previous studies from this and other groups have shown that GYY4137 releases 
H2S slowly in aqueous media and that the H2S release from this compound is 
sustainable for several hours or even days [97, 142]. In the present study, based 
on the chemical structure of GYY4137, a derivative of this compound i.e. 
FW1010 was synthesized in-house.  FW1010 in aqueous solution produced a 
sustained release of H2S over a 6 day period when incubated in cell culture 
medium. Moreover, the amount of H2S released from FW1010 was greater than 
H2S release from GYY4137 under the same experimental conditions over the 
same 6 days period. These results suggest that FW1010 is a novel i.e. previously 
unreported slow-releasing H2S donor.  
 
In recent years, numerous researchers have reported that H2S is capable of both 
pro- and anti-apoptotic effects in different cells maintained in culture [63, 143, 
144]. However, the precise mechanism(s) of these effects remain unclear. Our 
group has previously reported that the slow-releasing H2S donor, GYY4137 





distinctive anti-proliferative effect across a broad range of cancer cell lines but 
was devoid of anti-proliferative ability in normal cells i.e. non-cancer cell lines. In 
contrast, NaHS, which is known to release large amounts of H2S over a very short 
time course, failed to affect proliferation of either cancer or normal cell lines. This 
work therefore raised the intriguing possibility that H2S donors, with differing 
H2S-releasing kinetics, may be of value in killing cancer (but not normal) cell 
therapeutically.  
  
In the present study, both GYY4137 and FW1010 (but not NaHS) caused a 
concentration-dependent killing of different human cancer cells i.e. MCF-7 and 
MDA-MB-231 (human breast adenocarcinoma cell line), HepG2 (human liver 
hepatocellular cell line) and U2OS (human osteosarcoma cell line). Interestingly, 
FW1010 exhibited a greater killing effect than did GYY4137 in this regard. No 
such killing effect was detective in a normal (WI38, human diploid lung fibroblast) 
cell line.  In addition to the studies undertaken by our group, Chattopadhyay and 
colleagues [93] recently demonstrated that H2S inhibits cancer cell survival. This 
group reported that H2S-releasing non-steroidal anti-inflammatory drugs (HS-
NSAIDs) were able to reduce cancer cell survival in eleven cancer cell lines 
tested (i.e. human breast, colon, pancreatic, leukemia, lung and prostate cancer), 
thereby providing further evidence for a potential effect of H2S donors as anti-
cancer agents. In contrast, another study reported that NaHS, which releases 
rapidly H2S, promotes proliferation in human colon cancer cells and protects these 





donors (e.g. NaHS) and slow-releasing H2S donors (e.g. GYY4137, FW1010) 
have different effects on cancer cells, these results suggest that the duration of 
exposure of cancer cells to H2S may differentially affect their effects on survival. 
Thus, prolonged H2S exposure appears to promote cancer cell death whilst acute 
exposure to this gas either promotes or has a negligible effect on cancer cell 
viability. 
 
A recent review indicated that H2S has many differential anti-cancer effects and 
that H2S has the ability to inhibit of all stages of cancer development [107]. 
DATS, an organosulfur compound found in garlic [145] is capable of sustained 
H2S release [146]. Exposure of human gastric cell lines (SGC-7901 and MGC803) 
to DATS caused mitotic arrest and inhibition of cell proliferation [147]. Lau and 
colleagues [148] also reported that DATS causes apoptosis of a human gastric 
cancer cell line (BGC-823) and that this effect was associated with 
downregulation of Bcl2 and upregulation of caspase-3 expression and activity. 
Similarly, organic isothiocyanates, which also release H2S, exhibit cytotoxic 
effects in cancer cells by generation of reactive oxygen species [149-151]. 
Interestingly, in the present study, neither FW1010, GYY4137 nor NaHS caused 
significant killing of normal cells suggesting that the killing effect of these H2S 
donors is specific for cancer cells. Indeed, a strong concentration-dependent 
signal for cleaved-PARP was detected in MCF-7 samples treated with either 
GYY4137 or FW1010. Moreover, cleaved-PARP was regulated to a greater effect 





concentration of GYY4137. Thus, it may be proposed that both FW1010 and 
GYY4137 kill cancer cells under the present experimental concentrations via 
apoptosis. The ability of H2S to trigger death of cancer cells is supported by the 
findings of Lee and colleagues [98] who demonstrated that treatment of MCF-7 
cells with GYY4137 caused cell cycle arrest in the G2/M phase and promoted 
apoptosis as evidenced by increased sub-G1 population as well as the presence of 
both cleaved-PARP and cleaved-caspase 9. Essentially similar results were 
provided by Chattopadhyay and colleagues [93] using HS-NSAIDs which 
inhibited cancer cell survival by reducing cell proliferation, inducing apoptosis 
and initiating G0/G1 cell cycle block. 
 
Cancer cells exhibit a phenomenon referred to as the Warburg effect [150].  Using 
this mechanism, cancer cells maintain a state of high metabolic activity, required 
for constant cell replication, largely by switching energy production away from 
mitochondrial oxidative phosphorylation are towards glycolysis. One 
consequence of increasing glycolysis in cancer cells is intracellular acidification, 
which is a characteristic feature of cancer cells but not normal cells, which exhibit 
basal glycolytic rate and which usually harvest energy through oxidative 
phosphorylation [149, 150]. Given that the underlying mechanism of action of 
H2S in cancer cells appears to be associated with cellular metabolism in one form 
or another this fundamental difference between normal and cancer cell 
metabolism may help to explain the selective killing effect of H2S releasing 





Interestingly, considerable evidence suggests that manipulating tumor 
intracellular pH provides a plausible approach for cancer treatment as reviewed in 
a number of reports [131, 152-155]. Reducing the intracellular pH of cancer cells 
can promote apoptosis. A previous study from Lee and colleagues [132] showed 
that H2S was able to boost glycolysis in cancer cells as evidenced by increased 
glucose uptake and lactate production, after GYY4137 treatment. Moreover, 
GYY4137 impaired the activity of pH regulator molecules in these cells, resulting 
in intracellular acidification which further promoted the H2S killing effect. In the 
present study, both cancer and normal cells were treated with GYY4137 or 
FW1010 for 5 days but only cancer (not normal) cells showed evidence of 
increased glycolysis (i.e. augmented glucose consumption and lactate production) 
and associated decreased pHi. Moreover, FW1010, which triggers more killing of 
cancer cells (compared to GYY4137), also caused greater H2S-induced glucose 
consumption, lactate production and pHi reduction than did treatment with 
GYY4137. These results indicated that a combination of metabolic acid 
overproduction (glucose overconsumption and lactate overproduction) and pH 
homeostasis impairment might influence the sensitivity of cancer cells towards 
H2S-induced intracellular acidification 
 
The exact molecular targets by which H2S promotes cancer cell death are not 
clear at this moment. Given the high permeability and solubility of H2S in lipid as 
compared to aqueous buffer, H2S may accumulate within the plasma membrane 





bound protein complexes such as the glucose transporter (GLUT) and pH 
regulators including sodium/proton exchangers (NHEs), anion exchangers (AEs), 
carbonic anhydrases (CAs), proton-pump vacuolar ATPase (V-ATPase) and 
mononcarboxylate transporters (MCTs) [156]. For example, V-ATPase (a proton 
pump) plays an important role in regulating pHi and extracellular pH (pHe) in 
human breast cancer cells [157-159]. By pumping protons out of the cell, the V-
ATPase pump helps to maintain a relatively neutral pHi, an acidic luminal pH and 
an acidic pHe. Interestingly, V-ATPase is often overexpressed in metastatic 
cancers and its expression reportedly correlates positively with both metastasis 
and cancer cell invasion. AE1, a mammalian bicarbonate transporter, which also 
functions to regulate pHi has been shown to affect glycolysis [160]. AE1 acts as a 
scaffold for glycolytic enzyme assembly and facilitates glycolytic flux [161]. 
Hence, since the anti-cancer effect of H2S is also mediated by increased 
glycolysis it is reasonable to anticipate that cells with lower expression of AE1 
may be less affected by H2S-induced glycolytic flux effects. Furthermore, a recent 
report suggested that H2S impaired the activities of pH regulators (i.e. AEs and 
NHEs) in cancer cells and caused intracellular acidification inside cancer cells 
[132]. Intense intracellular acidification may therefore serve as a damaging 
stimulus [162] and trigger cancer cell death. In general, pHi plays a crucial role in 
modulating a range of cellular functions including cell metabolic processes, 
adhesion and death. In cancer cells, the function of pHi extends to include 
regulation of proliferation, invasion and metastasis as well as drug resistance 





energy production [140] and hence, they exhibit a greater propensity to 
intracellular acidification caused by lactate production, cancer cells rely heavily 
(more so than none cancer cells) on an effective pH homeostasis, to ensure their 
own survival.  
 
Moreover, Cuevasanta et al [156] reported that, compared to aqueous buffer, H2S 
had higher permeability and solubility in lipid, which suggests that H2S may 
accumulate within the plasma membrane bilayer. Our data shows that both 
FW1010 and GYY4137 increased glucose consumption, lactate production and 
reduced pHi. These events are all localized to the membrane.  Thus, it is 
suggested that H2S may affect the activity of those membrane-bound proteins 
such as the glucose transporter (GLUT) and pH regulator (V-ATPase) perhaps via 
post-translational modification sulfhydration. However, this possibility is 
unproven and warrants further investigation. 
 
The possible mechanisms of action shown by slow-releasing H2S donors such as 
FW1010 and GYY4137 in cancer cells are show in Figure 17. Both FW1010 and 
GYY4137 in aqueous solution cause sustained H2S release. On one hand, the H2S 
released likely interferes with the function of membrane-bound protein complexes 
such as the glucose transporter (GLUT), and then increases glycolysis (glucose 
consumption and lactate production) in cancer cells, which causes metabolic acid 
overproduction in the cancer cells. On the other hand, the sustained presence of 





homeostasis in cancer cells. The combined effect of defective pH regulation and 
increased glycolysis may well result in intense intracellular acidification causing 
damage and ultimately triggering apoptosis. This chain of events leads finally to 
cancer cell death. FW1010 releases more H2S than GYY4137, which probably 
underpins its enhanced cancer killing effect.  
 
In summary, this study has identified FW1010 as a novel slow-releasing H2S 
donor. More importantly, work reported in this thesis highlights a possible new 
approach to cancer therapy which exploits natural mechanistic differences in the 
metabolism of cancer (compared with normal) cells. In this way, H2S “overdrives” 
cancer glycolysis resulting in high metabolic acid production, coupled with 
impaired pH homeostasis, causing intense and uncontrolled intracellular 
acidification. As both of these mechanistic components are prominent in cancer, 









Figure 17.	   Schematic diagram representing the possible mechanisms 
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